So you are admitting that they need to "bypass" the FDA. Very interesting. I agree that the results of clinical trials to date have been inconclusive on Ropren.
Proper clinical trials that show no statistically significant positive effect for Ropren would be very damaging, so I agree that doing a full Phase III trial could be extremely hazardous to the Solagran share price. Best to keep the dodgy stuff in Russia.